AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $375.50 billion. The enterprise value is $439.62 billion.
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, before market open.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | Jul 15, 2025 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 73.85% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 101.21 and the forward PE ratio is 16.20. AbbVie's PEG ratio is 1.09.
| PE Ratio | 101.21 |
| Forward PE | 16.20 |
| PS Ratio | 6.44 |
| Forward PS | 5.83 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.59 |
| P/OCF Ratio | 19.47 |
| PEG Ratio | 1.09 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.66, with an EV/FCF ratio of 24.10.
| EV / Earnings | 118.08 |
| EV / Sales | 7.54 |
| EV / EBITDA | 15.66 |
| EV / EBIT | 22.20 |
| EV / FCF | 24.10 |
Financial Position
The company has a current ratio of 0.74
| Current Ratio | 0.74 |
| Quick Ratio | 0.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.48 |
| Debt / FCF | 3.87 |
| Interest Coverage | 6.92 |
Financial Efficiency
Return on equity (ROE) is 112.85% and return on invested capital (ROIC) is 16.70%.
| Return on Equity (ROE) | 112.85% |
| Return on Assets (ROA) | 8.87% |
| Return on Invested Capital (ROIC) | 16.70% |
| Return on Capital Employed (ROCE) | 20.33% |
| Revenue Per Employee | $1.06M |
| Profits Per Employee | $67,691 |
| Employee Count | 55,000 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 3.65 |
Taxes
| Income Tax | -741.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +7.89% in the last 52 weeks. The beta is 0.53, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | +7.89% |
| 50-Day Moving Average | 197.18 |
| 200-Day Moving Average | 189.66 |
| Relative Strength Index (RSI) | 71.37 |
| Average Volume (20 Days) | 4,378,396 |
Short Selling Information
The latest short interest is 17.00 million, so 0.96% of the outstanding shares have been sold short.
| Short Interest | 17.00M |
| Short Previous Month | 15.61M |
| Short % of Shares Out | 0.96% |
| Short % of Float | 0.96% |
| Short Ratio (days to cover) | 3.37 |
Income Statement
In the last 12 months, AbbVie had revenue of $58.33 billion and earned $3.72 billion in profits. Earnings per share was $2.10.
| Revenue | 58.33B |
| Gross Profit | 41.56B |
| Operating Income | 19.80B |
| Pretax Income | n/a |
| Net Income | 3.72B |
| EBITDA | 28.07B |
| EBIT | 19.80B |
| Earnings Per Share (EPS) | $2.10 |
Full Income StatementBalance Sheet
The company has $6.47 billion in cash and $70.59 billion in debt, giving a net cash position of -$64.12 billion or -$36.30 per share.
| Cash & Cash Equivalents | 6.47B |
| Total Debt | 70.59B |
| Net Cash | -64.12B |
| Net Cash Per Share | -$36.30 |
| Equity (Book Value) | -138.00M |
| Book Value Per Share | -0.10 |
| Working Capital | -10.51B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $19.28 billion and capital expenditures -$1.04 billion, giving a free cash flow of $18.24 billion.
| Operating Cash Flow | 19.28B |
| Capital Expenditures | -1.04B |
| Free Cash Flow | 18.24B |
| FCF Per Share | $10.32 |
Full Cash Flow StatementMargins
Gross margin is 71.25%, with operating and profit margins of 33.95% and 6.45%.
| Gross Margin | 71.25% |
| Operating Margin | 33.95% |
| Pretax Margin | 5.19% |
| Profit Margin | 6.45% |
| EBITDA Margin | 48.13% |
| EBIT Margin | 33.95% |
| FCF Margin | 31.27% |
Dividends & Yields
This stock pays an annual dividend of $6.56, which amounts to a dividend yield of 3.08%.
| Dividend Per Share | $6.56 |
| Dividend Yield | 3.08% |
| Dividend Growth (YoY) | 5.55% |
| Years of Dividend Growth | 53 |
| Payout Ratio | 308.07% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 3.06% |
| Earnings Yield | 0.99% |
| FCF Yield | 4.86% |
Dividend DetailsAnalyst Forecast
The average price target for AbbVie is $216.10, which is 1.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $216.10 |
| Price Target Difference | 1.67% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 7.33% |
| EPS Growth Forecast (5Y) | 50.84% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.14 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.14 |
| Piotroski F-Score | 6 |
